Resolution of platelet function defects with imatinib therapy in a patient with chronic myeloid leukaemia in chronic phase

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 1, 2009, Pages 81-83

  Ng, Ashley P ^a,b   Servadei, Patricia ^a   Tuckfield, Annabel ^a   Friedhuber, Anna ^a   Grigg, Andrew ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Bleeding; Chronic myeloid leukaemia; Imatinib; Platelet function defect

Indexed keywords

ADRENALIN; ARACHIDONIC ACID; COLLAGEN; IMATINIB; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ANAMNESIS; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CANCER PATIENT; CASE REPORT; CELL ULTRASTRUCTURE; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COMPARTMENT SYNDROME; DISEASE SEVERITY; DRUG RESPONSE; FASCIOTOMY; HEMATOMA; HEMOSTASIS; HUMAN; INJURY; LABORATORY TEST; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BLOOD PLATELET DISORDERS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PLATELET FUNCTION TESTS; PYRIMIDINES;

EID: 58849156368     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283177b03     Document Type: Article

References (11)

1. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 1997; 96: 111 -116.
2. Wehmeier A, Scharf RE, Fricke S, Schneider W. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease. Haemostasia 1989; 19: 251 -259.
3. O'Brien SG, Guilhot F, Larson RA, Gathmann l, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
4. Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 1991; 63: 101-106.
5. Baker Rl, Manoharan A. Platelet function in myeloproliferative disorders: characterìzatìon and sequential studies show multiple platelet abnormalities, and change with time. Eur J Haematol 1988; 40: 267-272.
6. ten Bosch GJ, Kessler JH, Blom J, Joosten AM, Gambacorti-Passerini C, Melief CJ, et al. BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation. Br J Haematol 1998; 103: 1109-1115.
7. Best D, Pasquet S, Littlewood TJ, Brunskill SJ, Pallister CJ, Watson SP. Platelet activation via the collagen receptor GPVI is not altered in platelets from chronic myeloid leukaemia patients despite the presence of the constitutively phosphorylated adapter protein CrkL. Br J Haematol 2001; 112: 609-615.
8. Boneu B, Nouvel C, Sie P. Caranobe C, Combes D, Laurent G, et al. Platelets in myeloproliferative disorders. l. A comparative evaluation with certain platelet function tests. Scand J Haematol 1980; 25: 214-220.
9. Caranobe C, Sie P, Nouvel C, Laurent G, Pris J, Boneu B. Platelets in myeloproliferative disorders. II. Serotonin uptake and storage: correlations with mepacrine labelled dense bodies and with platelet density. Scand J Haematol 1980; 25: 289-295.
10. Mohri H. Acquired von Willebrand disease and storage pool disease in chronic myelocytic leukemia. Am J Hematol 1986; 22: 391 - 401.
11. Poon MC, Zotz R, Di Minno G, Abrams ZS, Knudsen JB, Laurian Y. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol 2006; 43 (1 Suppl 1):S33-S36.